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Abstract
 
Transcription factors of the interferon regulatory factor (IRF) family contribute to the regu-
lation of cell proliferation and apoptosis. Here, we show that CD4
 
 
 
 T helper (Th) cells lack-
ing IRF4 (IRF4
 
   
 
) are highly sensitive to apoptosis. After infection of IRF4
 
   
 
 mice with
the protozoan parasite 
 
Leishmania major
 
, the lesion-draining lymph nodes developed the pro-
totypic lymphadenopathy of wild-type mice after 4 wk, but demonstrated almost total loss of
cellularity and enhanced apoptosis after 7 wk. In vitro, activation of IRF4
 
   
 
 CD4
 
 
 
 Th cells
led to greatly increased apoptosis compared with wild-type cells. Coculture of IRF4
 
   
 
 and
IRF4
 
   
 
 CD4
 
 
 
 cells did not increase survival of IRF4
 
   
 
 CD4
 
 
 
 cells, indicating that the en-
hanced rate of IRF4
 
   
 
 Th cell apoptosis was neither transferable nor due to lack of a cytokine.
Enhanced CD4
 
 
 
 cell apoptosis was also observed after anti-CD95 mAb treatment, despite
normal CD95 expression. Removal of endogenous cytokines, notably interleukin (IL)-4, led
to increased and equally high levels of IRF4
 
   
 
 and IRF4
 
   
 
 cell apoptosis, whereas the pro-
tective activity of exogenous IL-4 was reduced in IRF4
 
   
 
 CD4
 
 
 
 cells despite normal ex-
pression of the IL-4 receptor. Therefore, IRF4 is central in protecting CD4
 
 
 
 cells against
proapoptotic stimuli.
Key words: Th cell • apoptosis • IRF4 • CD95 • 
 
Leishmania major
 
 • T helper cell • IL-4
 
Introduction
 
The IFN regulatory factor (IRF) family of transcription
factors includes the IRF1-IRF7 proteins, IFN-stimulated
gene factor 3 
 
 
 
, and IFN consensus sequence-binding
protein (ICSBP; reference 1). IRF proteins bind to regu-
latory elements found in the promoters of IFN-inducible
genes. IRF1, IRF2, and ICSBP are mandatory for normal
Th1 cell differentiation due to their ability to induce IL-12
(2–5). IRF1 and IRF2 have also been implicated in the
regulation of cell proliferation (6). Recently, striking im-
mune defects were found in mice lacking IRF4, including
impaired antibody production, almost absent antiviral cy-
totoxic T cell responses, and deficient Th2 cell differenti-
ation of CD4
 
 
 
 T cells (7–9). IRF4 may also influence the
life span of lymphocytes because IRF4
 
   
 
 mice develop
progressive lymphadenopathy (7) and because overexpres-
sion of IRF4 leads to enhanced apoptosis in human Jurkat
cells (10).
Herein, we have studied the role of IRF4 in T cell sur-
vival in more detail in vivo and in vitro using IRF4
 
   
 
mice. For the in vivo studies, mice were infected with the
protozoan parasite 
 
Leishmania
 
 
 
major
 
. In mouse strains re-
sistant to this infection (e.g., C57BL/6), 
 
L. major
 
–spe-
cific Th1 cells expand and control the disease (11). We
demonstrate that in 
 
L. major
 
–infected IRF4
 
   
 
 mice of the
C57BL/6 genotype, initial hyperplasia is followed by
strongly enhanced apoptosis in the lesion-draining LNs.
This finding correlates with enhanced apoptosis of IRF4
 
   
 
Th cells after TCR or CD95 triggering, a surprising result
in light of the spontaneous lymphadenopathy in IRF4
 
   
 
animals and the conflicting results reported in Jurkat cells.
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Materials and Methods
 
Mice.
 
IRF4
 
   
 
 mice (7) were used at the seventh backcross
generation to C57BL/6. Wild-type C57BL/6, BALB/c, and
C57BL/6-CD45.1 congenic mice were purchased from Charles
River Laboratories. RAG-1–deficient mice were bred at Ta-
conic. All mice used were between 6 and 12 wk of age. All ex-
periments were conducted in accordance with German and Ca-
nadian animal protection laws.
 
Cell Purification and Adoptive Transfer into RAG-1
 
   
 
 Mice.
 
C57BL/6 B cells and IRF4
 
   
 
 as well as IRF4
 
   
 
 CD4
 
 
 
 Th cells
were purified by magnetic cell sorting using the MACS system
(Miltenyi Biotec) as described previously (3). The purity of these
cells was always 93–98%. B cells (9 
 
 
 
 10
 
6
 
) and CD4
 
 
 
 IRF4
 
   
 
 or
IRF4
 
   
 
 cells (6 
 
 
 
 10
 
6
 
) were transferred i.p. into RAG-1
 
   
 
mice (3–4 mice per experimental group). After cell transfer, these
mice were infected with 
 
L. major
 
 promastigotes as described in
the next paragraph and analyzed 6 wk later. All experiments were
performed at least twice with similar results.
 
Leishmania Infection and Apoptosis In Vivo.
 
Mice (3–4 per
group) were infected in the right hind footpad with 2 
 
 
 
 10
 
7
 
 sta-
tionary-phase promastigotes of 
 
L. major
 
 strain MHOM/IL/81/
FEBNI as described previously (3). Lesion development as well as
parasite burden were determined as described previously (3).
Apoptosis within LNs of infected mice was investigated 5 wk af-
ter 
 
L. major
 
 infection by the immediate processing of single cell
suspensions for a TdT-mediated dUTP nick-end labeling (TUNEL)
reaction and flow cytometric analysis (In Situ Cell Death kit;
Boehringer). LNs were fixed and processed for hematoxylin eosin
(HE) staining according to standard procedures.
 
Th Cell Stimulation In Vitro.
 
Total CD4
 
 
 
 Th cells from
IRF4
 
   
 
 or 
 
   
 
 mice were purified using the first steps of the
multisort kit (Miltenyi Biotec) as described previously (5). 10
 
6
 
/ml
of purified Th cells were stimulated in vitro for 72 h with 5 
 
 
 
g/
ml of immobilized anti-CD3 mAb, 2.5 
 
 
 
g/ml of soluble anti-
CD28 mAb (BD Biosciences), or 100 U/ml of recombinant hu-
man IL-2 as described previously (5). After a resting period of 48–
72 h in the absence of anti-CD3 mAb, but in the presence of
IL-2, viable cells were purified on a Ficoll density gradient and
restimulated in the presence of IL-2 either with anti-CD3 (im-
mobilized at 5 
 
 
 
g/ml) or with 1 
 
 
 
g/ml of soluble anti-Fas mAb
Jo2 (Becton Dickinson) together with 2 
 
 
 
g/ml of protein G
(Sigma-Aldrich). Apoptosis was analyzed by annexin V and pro-
pidium iodide (PI) staining as described previously (12) at the in-
dicated times after secondary stimulation. Viable as well as dead
cells were included in this analysis according to forward and side
scatter characteristics. The role of CD95L during apoptosis was
analyzed either by staining with PE-conjugated anti-CD95L
mAb (Becton Dickinson) or by inclusion of a neutralizing anti-
CD95L mAb (clone K10; 10 
 
 
 
g/ml; Becton Dickinson) during
restimulation. The CD95 molecule was stained using biotinylated
mAb Jo2 detected by FITC-conjugated streptavidin (Becton
Dickinson). Cells were analyzed on a FACScan™ using Lysys II
software (Becton Dickinson). In experiments where IRF4
 
   
 
 
 
and
CD45.1 congenic CD4
 
 
 
 Th cells were mixed, they were distin-
guished by staining with anti-CD45.2 mAb (Becton Dickinson)
and PE-conjugated anti–mouse IgG Ab (Dianova).
 
Results and Discussion
 
Enhanced Apoptosis within Lesion-draining LN Cells of L.
major–infected IRF4
 
   
 
 Mice.
 
To determine the role of
IRF4 for the immune response during an infection, IRF4
 
   
 
and IRF4
 
   
 
 mice were infected with 
 
L. major
 
 parasites.
4 and 7 wk later, the number of viable cells in the le-
sion-draining popliteal LNs was determined after staining
Figure 1. Enhanced cell apoptosis in draining LNs of L. major–infected
IRF4    mice. (A–D) 5 wk after L. major infection, single cell suspensions
of popliteal LN cells were processed for TUNEL staining and analyzed by
flow cytometry. (E and F) HE-staining of popliteal LNs. (A and C–E)
IRF4    mice. (B and F) IRF4    mice. (A–C, E, and F) Draining
popliteal LNs. (D) Irrelevant axillary LNs. (C) Control staining for
IRF4    mice without the TdT enzyme. (y axis) staining for apoptotic
cells (FITC). Numbers indicate the percentage of apoptotic cells located
in the top left quadrant. Arrows in E indicate clusters of apoptotic cells.
Three independent experiments were performed with similar results.
(G) Increase in lesion size: IRF4    and IRF4    as well as control sus-
ceptible BALB/c and resistant C57BL/6 mice were infected with L. major,
and the increase in lesion size was monitored, as described previously
(reference 3). 
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with trypan blue. In uninfected mice of either genotype,
popliteal LNs contained 
 
 
 
10
 
6
 
 cells. At 4 wk after infection,
the cell number per LN had increased equally in IRF4
 
   
 
and IRF4
 
   
 
 mice to 
 
 
 
30 
 
 
 
 10
 
6
 
. Significantly, by 7 wk af-
ter infection, popliteal LN of IRF4
 
   
 
 mice still contained
 
 
 
15 
 
 
 
 10
 
6
 
 cells, whereas in popliteal IRF4
 
   
 
 LNs, the
cell number had virtually dropped to zero (
 
 
 
10
 
5
 
 cells/LN).
In contrast, cell numbers in IRF4
 
   
 
 LNs not draining the
infectious lesion were either comparable to the respective
IRF4
 
   
 
 LNs or higher as a reflection of the progressive
lymphadenopathy of IRF4
 
   
 
 mice (7). While our work
was in progress, a similar finding was reported by another
group, although without further analysis of this phenome-
non (13).
The disappearance of popliteal IRF4
 
   
 
 LNs was due to
apoptosis, as analyzed 5 wk after 
 
L. major
 
 infection by im-
mediate processing of LN cells for TUNEL staining. At this
time, the destruction of the draining LNs was not yet com-
plete. Cells in draining IRF4
 
   
 
 LNs (Fig. 1 A) exhibited a
rate of apoptosis almost six times higher than that in
IRF4
 
   
 
 LNs (Fig. 1 B). No enhanced rate of apoptosis
was noted in the irrelevant axillary IRF4
 
   
 
 LNs (Fig. 1
D). Histological examination confirmed these findings:
apoptotic cells were detectable in the draining LNs of
IRF4
 
   
 
 (Fig. 1 E), but not of IRF4
 
   
 
 mice (Fig. 1 F). LN
cell apoptosis correlated with an increase in lesion size (Fig.
1 G) and with a strongly increased parasite burden as fol-
lows: 7 wk after infection, footpads of IRF4
 
   
 
 mice con-
tained log 7.3 
 
  0.6 parasites versus log 2.6   0.3 in
IRF4    mice. Spleens of IRF4    mice harbored log
6.6   0.3 parasites versus log 3.2   0.4 in IRF4    mice.
Because CD4  Th cells are a major component of the
hyperplastic LN after L. major infection (11), it was possible
that IRF4    Th cells are prone to activation-induced
apoptosis. To analyze this issue, we adoptively transferred
purified IRF4    B cells plus CD4  T cells from either
IRF4    or IRF4    mice into IRF4    RAG-1–deficient
mice that otherwise lack T and B cells. The recipients were
infected with L. major and their popliteal LNs were ana-
lyzed 6 wk later. Although the draining LNs of mice re-
ceiving IRF4    CD4  T cells contained 8.0   1.7   105
cells, this number was  5   104 in each of three mice re-
ceiving IRF4    CD4  T cells. Thus, even though not for-
mally proving enhanced apoptosis, the number of IRF4   
CD4  T cells in vivo was strongly reduced compared with
that of IRF4    CD4  T cells, even in an environment in
which all other cells were competent with respect to
IRF4.
Enhanced Apoptosis of TCR-triggered IRF4    CD4  T
Cells In Vitro. Next, we asked whether IRF4    Th cells
exhibit alterations during activation-induced cell death
(AICD; reference 14) in vitro. Total CD4  IRF4    and
IRF4    Th cells were purified and stimulated for 72 h via
their TCRs using anti-CD3 mAb in the presence of anti-
CD28 mAb and IL-2. After a resting period of 72 h in the
absence of anti-CD3, but with the presence of IL-2, viable
cells were restimulated via anti-CD3 mAb. Apoptosis was
determined 10 h later by flow cytometry using forward and
side scatter characteristics as indicators of cell morphology
(Fig. 2 A), as well as by annexin V and PI staining. In all
experiments, both methods yielded comparable results;
representative results are depicted in Fig. 2 A (bottom) and
Fig. 2 B. Therefore, throughout this paper, results for only
one of the two methods will be presented.
Considerably more IRF4    Th cells than IRF4    Th
cells survived restimulation by anti-CD3. In contrast, the
percentage of viable cells was equal in IRF4    and IRF4   
Th cell populations restimulated only with IL-2 (Fig. 2 A,
top). To normalize for IL-2 concentration, saturating
amounts of human IL-2 were added in all experiments. In
Figure 2. Enhanced TCR-induced apoptosis of IRF4    Th cells in
vitro. IRF4    (wt) and IRF4    Th cells were stimulated for 72 h with
anti-CD3/CD28 mAb, rested for 72 h, and restimulated with IL-2 with
or without anti-CD3 mAb, as indicated. In C, restimulation was per-
formed in the presence of anti-CD95L mAb. After 10 h, flow cytometry
was used to show cell morphology (A and C) or apoptosis after staining
with annexin V and PI (B). Numbers refer to the percentage of viable
cells depicted in the polygon (A and C) or bottom left quadrant (B). The
results are representative of three different experiments.IRF4 and T Helper Cell Apoptosis 250
control experiments, increased apoptosis was specific for
IRF4 deficiency and not found in IRF2    Th cells (un-
published data).
Mediation of Enhanced IRF4    Th Cell Apoptosis by a
Cell-intrinsic Process. A major part of AICD is mediated
through interaction of CD95 with its ligand CD95L (14).
To analyze this interaction in IRF4    and IRF4    Th
cells, cells were primed, followed by a resting phase, as
aforementioned. However, restimulation was performed in
the presence of a neutralizing antibody directed against
CD95L. Anti-CD95L mAb significantly blocked apoptosis
in both cell populations, but its efficacy was much higher
in IRF4    Th cells; the ratio of viable IRF4    versus
IRF4    Th cells shifted from 5:1 without anti-CD95L
mAb to 2:1 in its presence (Fig. 2 C). At this time point,
expression of CD95 and CD95L was similar in cells of both
genotypes (unpublished data). These results suggest that the
enhanced apoptosis of IRF4    Th cells is due to signaling
events downstream of CD95.
Next, death was induced by restimulation with an ago-
nistic anti-CD95 mAb and cross-linked by protein G (Fig.
3 A) in the absence of anti-CD3. As before, IRF4    Th
cells were much more susceptible to apoptosis. This result
was specific to the presence of anti-CD95 mAb, but not of
protein G alone (Fig. 3 A) or of control IgG plus protein G
(not depicted). The same result was obtained when the
sub-G0 cell fraction was determined as a parameter of
apoptosis (Fig. 3 B).
To test if the augmentation of IRF4    Th cell apoptosis
was due to fratricide, or to lack of a cytokine, we took ad-
vantage of Th cells of the C57BL/6 background congenic
for the CD45.1 gene. Such cells can be identified by a mAb
that stains the CD45.2, but not the CD45.1 allotype.
CD45.2 IRF4    and CD45.1 IRF4    CD4  Th cells
were purified, mixed, and stimulated by anti-CD3/CD28 as
aforementioned. In the first experiments of this kind, it was
noted that IRF4    Th cells, despite comparable viability,
have a 3–4-fold growth advantage over IRF4    Th cells.
Thus, in a typical experiment, one well of IRF4    Th cells
contained 0.80   106   0.0106 cells after stimulation and
resting, whereas a well of IRF4    Th cells contained 2.40  
106   0.05   106. Therefore, to account for this difference
in proliferation, CD45.2 IRF4    and CD45.1 IRF4   
cells were mixed at a ratio of 4:1 at the beginning of the ex-
periment. After resting, the mixed cells were triggered via
CD95 for 4 h, stained with anti-CD45.2 mAb, and gated vi-
able cells were analyzed by flow cytometry (Fig. 3 C). Mixed
control cells without anti-CD95 mAb treatment consisted of
CD45.2 IRF4    and CD45.1 IRF4    cells at a ratio of
1:1. In contrast, anti-CD95 mAb treatment led to an almost
total disappearance of viable IRF4    Th cells. These data
demonstrate that the enhanced death of IRF4    Th cells
characteristics were gated. Numbers indicate the percentage of viable
IRF4    (top) or CD45.1 congenic IRF4    (bottom) Th cells. For better
visibility, a two-dimensional plot for fluorescence intensity in the FITC
and PE channels is shown despite a one-color staining. Two experiments
were performed with similar outcome.
Figure 3. A cell-intrinsic mechanism mediates the augmented apopto-
sis of IRF4    Th cells. (A and B) IRF4    and IRF4    Th cells were
primed as in Fig. 2 and rested for 48 h. Restimulation was performed for
4 h in the presence or absence of anti-CD95 mAb. (A) Cells were ana-
lyzed as in Fig. 2 B. (B) Cell cycle analysis using propidium iodide (PI)
was performed as described previously (reference 10). The percentage of
dead cells in the sub-G0 fraction (located in region M3) is indicated.
(C) CD45.2 IRF4    and CD45.1 IRF4    CD4  Th cells were purified,
mixed at a ratio of 4:1, stimulated, rested, and triggered by anti-CD95
mAb as in A. After 4 h, IRF4    Th cells were detected using anti-
CD45.2 mAb (y axis). Viable cells according to forward and side scatterLohoff et al. Brief Definitive Report 251
cannot be conferred on IRF4    cells. Also, IRF4    Th
cells are not simply defective producers of a protective cyto-
kine. Rather, their increased apoptosis is most likely caused
by a deregulated cell-intrinsic program.
Soluble Factors Including IL-4 Influence Apoptosis of WT and
IRF4    Th Cells. Among other factors, IL-4 protects
cells from Fas-mediated apoptosis, as shown previously in
B cells and thyrocytes (15, 16). Significantly, IRF4    Th
cells display a defect in their response to IL-4, namely a
dramatically reduced differentiation into Th2 cells (8, 9,
13). Thus, different levels of apoptosis in IRF4    and
IRF4    Th cells could be due to a different response to
endogenous cytokines such as IL-4. To test this hypothesis,
IRF4    and IRF4    Th cells were stimulated as afore-
mentioned. However, before transferring cells and super-
natants into cultures without anti-CD3 mAb, half of the
cells were washed, followed by culture with IL-2. After an-
other 48 h, cell death was triggered by anti-CD95 mAb.
Removal of supernatants strongly increased the sensitivity
toward CD95-mediated death in IRF4    and IRF4    Th
cells (Fig. 4 A). Yet in most experiments, a significant dif-
ference in the respective levels of apoptosis remained.
Therefore, a soluble factor protected IRF4    and IRF4   
Th cells from apoptosis, but with and without cytokines,
IRF4    cell apoptosis was still significantly increased (un-
published data). A possible explanation for this outcome
was that cytokines had already partially protected IRF4   
Th cells before the supernatants were removed.
Because IL-4 was the most likely cytokine candidate for
protection, it was now either neutralized or added in satu-
rating amounts during primary stimulation and resting, un-
til anti-CD95 mAb was added (Fig. 4 B). Neutralization of
IL-4 increased the rate of apoptosis to almost identical lev-
els in both IRF4    and IRF4    Th cells. In contrast, the
addition of IL-4 protected IRF4    Th cells from apopto-
sis. However, significant apoptosis still occurred in IRF4   
Th cells, despite normal expression of the IL-4 receptor
(unpublished data) and normal Stat6 phosphorylation in re-
sponse to IL-4 (9).
Therefore, the increased susceptibility of IRF4    Th
cells toward apoptosis is mediated at least in part by an al-
tered response to IL-4, which also leads to their defective
IL-4–dependent Th2 differentiation (8, 9, 13). Of course,
IL-4 may not be the only protective cytokine at work in
this system, although we have excluded an activity of ex-
ogenous IL-15, a known protective cytokine (17). In vivo,
a reduced response to IL-4 may be exacerbated by defec-
tive Th2 cell differentiation, and this combination may ex-
plain the phenotype seen in the LNs of L. major–infected
IRF4    mice.
Different intracellular molecules have been implicated
in IL-4–mediated protection from apoptosis. Examples are
c-FLIP and BCL-XL in thyrocytes and BCL-XL in B cells
(15, 16). In Th cells, a candidate molecule is Gfi-1 be-
cause it is induced by IL-4 and inhibits apoptosis through
unknown mechanisms (18). c-FLIP is probably not in-
volved in the increased apoptosis of IRF4    Th cells
because we have indications that enhanced death can
be triggered not only via CD95, but also by other stim-
uli, such as  -irradiation (unpublished data). This finding
likely places the responsible molecules downstream of
Figure 4. Role of IL-4 in the augmented apoptosis of IRF4    Th cells.
(A and B) IRF4    and IRF4    cells were primed for 72 h, rested for 48 h,
and restimulated as in Fig.3 A. (A) At the start of the resting period, cells
were either left unwashed or underwent extensive washing. (B) Cells were
cultured with 10 ng/ml IL-4 or anti–IL-4 mAb, as indicated, for the duration
of the experiment. (A and B) Apoptosis was triggered and evaluated after 4 h
as in Fig. 3 A. Numbers indicate the percentage of viable cells present in the
bottom left quadrant. The numbers were normalized for the percentage of
viable cells cultured without anti-CD95 mAb in the respective condition.
Three experiments were performed with a similar outcome.IRF4 and T Helper Cell Apoptosis 252
CD95 and its antiapoptotic regulator c-FLIP. Accord-
ingly, we found similar c-FLIP expression in IRF4    and
IRF4    Th cells (unpublished data). Apoptosis of IRF4   
Th cells was inhibited by a nonspecific caspase inhibitor,
and procaspase-3 was cleaved more completely in IRF4   
as compared with IRF4    Th cells (unpublished data).
Therefore, our current analysis focuses on molecules up-
stream of caspase-3 and present in pathways triggered by
different apoptotic stimuli. However, levels of BCL-XL
and BCL-2 do not explain the difference because their
expression was similar in IRF4    and IRF4    Th cells
(unpublished data).
Finally, we would like to discuss a paper recently pub-
lished in this journal that is in conflict with our observa-
tions (10). Fanzo et al. showed convincingly that, in human
Jurkat cells, overexpressed IRF4 actually leads to enhanced
apoptosis and not to protection, as would be expected from
our results. The observation that IRF4 can suppress tran-
scription when operating alone or in cooperation with
ICSBP, while activating transcription in complex with dif-
ferent partners such as PU.1, may account for this discrep-
ancy. Possibly, it is not IRF4 itself, but rather the availabil-
ity of its diverse binding partners that determines whether
IRF4 is pro- or antiapoptotic. As an example, in HTLV-I–
infected leukemia cells, IRF4 is overexpressed and seems to
be antiapoptotic (19), a finding that is also divergent to the
report on Jurkat cells. Such considerations may also explain
why IRF4    mice, despite their apoptotic LN cells during
leishmaniasis, eventually suffer from lymphadenopathy (7),
possibly as a first step of malignant transformation.
In addition, Fanzo et al. also presented studies with T
cells from IRF4    mice. In their analysis, these T cells ap-
peared to be protected from proapoptotic stimuli. Although
we used the same mouse strain in our work, we obtained
opposite results as follows: IRF4    Th cells showed in-
creased apoptosis in  15 different experiments. In addition,
increased resistance to apoptosis was not noted in IRF4   
Th cells when cultured under the conditions described by
Fanzo et al., as determined by annexin V staining, forward
and side scatter characteristics, or by sub-G0 determination
after PI staining (Fig. 3 B). In our analysis, the protocol used
by this paper to prime T cells (1  g/ml anti-CD3, no anti-
CD28) left a significant fraction of IRF4    Th cells small
and probably unstimulated (unpublished data). Likely, these
cells are not as susceptible to AICD as cells primed accord-
ing to our protocol (5  g/ml anti-CD3 plus anti-CD28).
Therefore, despite the different results, our data support a
protective role of IRF4 during AICD of T helper cells.
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